Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum

• Published in: Neurology Vol. 101; no. 21; p. e2162
• Main Authors: Yoon, So Hoon, Kim, Han-Kyeol, Lee, Jae-Hoon, Chun, Joong-Hyun, Sohn, Young H, Lee, Phil Hyu, Ryu, Young Hoon, Cho, Hanna, Yoo, Han Soo, Lyoo, Chul Hyoung
• Format: Journal Article
• Language: English
• Published: United States 21.11.2023
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - complications; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - pathology; Amyloid - metabolism; Amyloid beta-Peptides - metabolism; Amyloidogenic Proteins; Atrophy - pathology; Brain - pathology; Cognitive Dysfunction; Disease Progression; Female; Humans; Male; Positron-Emission Tomography; Retrospective Studies; Sleep; tau Proteins - metabolism
• DOI: 10.1212/WNL.0000000000207917

Patients with Alzheimer disease (AD) frequently suffer from various sleep disturbances. However, how sleep disturbance is associated with AD and its progression remains poorly investigated. We investigated the association of total sleep time with brain amyloid and tau burden, cortical atrophy, cognitive dysfunction, and their longitudinal changes in the AD spectrum. In this retrospective cohort study, we enrolled participants on the AD spectrum who were positive on F-florbetaben (FBB) PET. All participants underwent the Pittsburgh Sleep Quality Index, brain MRI, FBB PET, F-flortaucipir (FTP) PET, and detailed neuropsychological testing. In addition, a subset of participants completed follow-up assessments. We analyzed the association of total sleep time with the baseline and longitudinal FBB-standardized uptake value ratio (SUVR), FTP-SUVR, cortical thickness, and cognitive domain composite scores. We examined 138 participants on the AD spectrum (15 with preclinical AD, 62 with prodromal AD, and 61 with AD dementia; mean age 73.4 ± 8.0 years; female 58.7%). Total sleep time was longer in the AD dementia group (7.4 ± 1.6 hours) compared with the preclinical (6.5 ± 1.4 hours; = 0.026) and prodromal groups (6.6 ± 1.4 hours; = 0.001), whereas other sleep parameters did not differ between groups. Longer total sleep time was not associated with amyloid accumulation but rather with tau accumulation, especially in the amygdala, hippocampus, basal forebrain, insular, cingulate, occipital, inferior temporal cortices, and precuneus. Longer total sleep time predicted faster tau accumulation in Braak regions V-VI (β = 0.016, = 0.007) and disease progression to mild cognitive impairment or dementia (hazard ratio = 1.554, = 0.024). Longer total sleep time was also associated with memory deficit (β = -0.19, = 0.008). Prolonged total sleep time was associated with tau accumulation in sleep-related cortical and subcortical areas as well as memory dysfunction. It also predicted faster disease progression with tau accumulation. Our study highlights the clinical importance of assessing total sleep time as a marker for disease severity and prognosis in the AD spectrum.